Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) traded up 6.4% during mid-day trading on Tuesday . The company traded as high as $5.19 and last traded at $5.15, with a volume of 539,096 shares trading hands. The stock had previously closed at $4.84.

A number of equities research analysts have issued reports on the company. Chardan Capital restated a “buy” rating and set a $10.00 price objective on shares of Aralez Pharmaceuticals in a research report on Sunday. Guggenheim reaffirmed a “buy” rating and set a $12.00 target price on shares of Aralez Pharmaceuticals in a research note on Monday.

The company’s 50-day moving average price is $3.82 and its 200-day moving average price is $4.25. The firm’s market cap is $322.29 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its earnings results on Tuesday, August 9th. The company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.08. The firm earned $12.60 million during the quarter, compared to analysts’ expectations of $9.70 million. The business’s revenue was up 142.3% compared to the same quarter last year. Equities analysts forecast that Aralez Pharmaceuticals Inc. will post ($0.99) EPS for the current year.

In other news, insider James Patrick Tursi acquired 10,000 shares of the stock in a transaction that occurred on Friday, May 20th. The shares were bought at an average cost of $3.75 per share, for a total transaction of $37,500.00. Following the acquisition, the insider now owns 179,368 shares in the company, valued at approximately $672,630. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.